SABio: RNA, Antibodies, Peptides and Other Quality Biologics
orders@sabio.com.sg
  • Home
  • Products & Services
    • siRNA & miRNA
    • Tranfection Reagents
    • siRNA Libraries
    • RNA Oligos
    • RNA Gel Markers
    • Antibodies
    • Antibody Production
    • Peptides
    • Human VEGF-C & D
    • How to Order
  • News
  • About Us
  • Contact Us
    • Contact Info
    • Directions
    • Careers at SABio

SABio Now Offers Synthetic Peptides

9/15/2012

1 Comment

 
Picture
SABio now offers peptides in additions to other quality biologics such as RNA oligos, siRNA and antibodies.
We are pleased to announce that SABio has added synthetic peptides to the catalogue of its quality biologics.

Please visit our peptide page for more information or request your custom quotation by filling this easy online form.


We offer:

  • Standard 5-30-mer peptides
  • Longer (>30aa) peptides
  • Amounts from milligrams to grams
  • Purity level of your choice – from crude to >98%
  • Variety of modifications (N-, C-terminal, intra-sequence, special amino acids etc.)
  • Mass spectral analysis and HPLC tracing reports included with each order
  • Competitive pricing & volume discounts for large orders

1 Comment

SABio Appoints Kristina Rutkute Managing Director

9/1/2012

0 Comments

 
Picture
Dr. Kristina Rutkute
Singapore, 1 September 2012. Singapore Advanced Biologics (“SABio”) announced today the appointment of Dr Kristina Rutkute to the position of Managing Director.  Dr. Rutkute has more than 10 years of experience in the biotech industry and research, covering a broad spectrum from assay development to quality assurance and business partnerships.

“We are delighted to have been able to attract Kristina to join the SABio team initially as the business development manager and congratulate her on the current appointment as the Managing Director of SABio ” said A/Prof Subhash Vasudevan,  a founder and member of the Board of Directors of SABio.  
“Kristina’s demonstrated success in engaging critical stakeholders of the companies where she has worked and her focused leadership style will be critical as we work to grow SABio and bring its products to the market” said Mr Damien Lim, General Partner of BioVeda Capital and a member of the SABio board.

Said Dr. Rutkute, “I look forward to lead and continue to grow SABio into a profitable company that can serve the biologics needs of the research communities in the universities, research institutes, academic medicine centers of public hospitals and biotech/pharmaceutical companies in Singapore and the region.”

Dr. Rutkute was previously with Acumen Research Laboratories, and the Institute of Molecular & Cell Biology at A*STAR.  She received her B.Sc in Biochemistry and a M.Sc in Medical Biology from Vilnius University, Lithuania, and a Ph.D. in Physiology from the University of Kentucky, College of Medicine, USA.
0 Comments

    Archives

    March 2022
    February 2014
    November 2013
    October 2013
    September 2013
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    February 2012
    January 2012
    September 2011
    April 2011

    Categories

    All
    Antibodies
    Events
    Peptides
    Sabio In The News
    Sabio Team
    Sirna

    RSS Feed

Powered by Create your own unique website with customizable templates.